Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.

The Lancet Oncology
Michael FriedlanderEric Pujade-Lauraine

Abstract

In the phase 3 SOLO2 trial (ENGOT Ov-21), maintenance therapy with olaparib tablets significantly prolonged progression-free survival (primary endpoint) compared with placebo in patients with a germline BRCA1 or BRCA2 (BRCA1/2) mutation and platinum-sensitive, relapsed ovarian cancer who had received two or more lines of previous chemotherapy. The most common subjective adverse effects included fatigue, nausea, and vomiting, which were typically low grade and self-limiting. Our a-priori hypothesis was that maintenance olaparib would not negatively affect health-related quality of life (HRQOL) and additionally that the prolongation of progression-free survival with olaparib would be underpinned by additional patient-centred benefits. In SOLO2, 196 patients were randomly assigned to olaparib tablets (300 mg twice daily) and 99 to placebo. Randomisation was stratified by response to previous chemotherapy (complete vs partial) and length of platinum-free interval (>6-12 vs >12 months). The prespecified primary HRQOL analysis evaluated the change from baseline in the Trial Outcome Index (TOI) score during the first 12 months of the study. To be assessable, patients had to have an evaluable score at baseline and at least one evaluabl...Continue Reading

Citations

Nov 6, 2018·BMJ : British Medical Journal·Bishal GyawaliYuichi Ando
Feb 23, 2019·Current Opinion in Oncology·Haven R Garber, Jennifer K Litton
May 18, 2019·CA: a Cancer Journal for Clinicians·Stephanie LheureuxAmit M Oza
May 24, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Emily HinchcliffRobert L Coleman
Sep 14, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ursula A MatulonisMansoor R Mirza
Mar 22, 2019·The Oncologist·Leslie M RandallThomas J Herzog
Apr 12, 2020·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Ainhoa MadariagaStephanie Lheureux
Aug 26, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amit M OzaRobert L Coleman
Nov 19, 2019·Experimental Hematology & Oncology·Ming YiSuxia Luo
Nov 23, 2019·Expert Opinion on Emerging Drugs·Asaf MaozKoji Matsuo
Feb 13, 2020·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Domenica LorussoValentina Guarneri
Jul 31, 2020·Signal Transduction and Targeted Therapy·Qiao WangXia Zhao
Nov 21, 2018·Targeted Oncology·Young-A Heo, Sohita Dhillon
May 28, 2020·Frontiers in Oncology·Praveen VikasRohan Garje
Jul 18, 2020·Indian Journal of Cancer·Zarka Samoon, Adnan Abdul Jabbar
Mar 22, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sarah A Cook, Anna V Tinker
Apr 10, 2020·Frontiers in Oncology·Yuichiro HatanoAkira Hara
Jun 18, 2019·Therapeutic Advances in Medical Oncology·Jonathan A Ledermann, Eric Pujade-Lauraine
Oct 19, 2019·Targeted Oncology·Esha SachdevMonica M Mita
Feb 23, 2020·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Rebecca ArendRobert L Coleman
Aug 14, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sara BouberhanStephen A Cannistra
Jun 10, 2020·Cells·Sandra Muñoz-Galván, Amancio Carnero
Nov 8, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Kate RosenEmerson Y Chen
Dec 6, 2020·Obstetrics and Gynecology·Katherine C KurnitErnst Lengyel
Feb 23, 2021·Gynecologic Oncology·Jean-Emmanuel KurtzUNKNOWN Gynecologic Cancer InterGroup (GCIG) symptom benefit committee
Oct 22, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chung Ying ChanBart Cornelissen
May 4, 2021·Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology·Apichaya TechataKittipat Charoenkwan
Mar 18, 2021·Journal of the National Cancer Institute·Lari WenzelMichael Birrer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.